Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0 2,6]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 15, 2010, Pages 4491-4495

  Xiao, Hai Yun ^a   Balog, Aaron ^a   Attar, Ricardo M ^a   Fairfax, David ^b   Fleming, Linda B ^b   Holst, Christian L ^b   Martin, Gregory S ^b   Rossiter, Lana M ^b   Chen, Jing ^a   Cvjic, Mary Ellen ^a   Dell John, Janet ^a   Geng, Jieping ^a   Gottardis, Marco M ^a   Han, Wen Ching ^a   Nation, Andrew ^a   Obermeier, Mary ^a   Rizzo, Cheryl A ^a   Schweizer, Liang ^a   Spires Jr , Thomas ^a   Shan, Weifang ^a   Gavai, Ashvinikumar ^a   Salvati, Mark E ^a   Vite, Gregory ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b Albany Molecular Research Institute   (United States)

Author keywords

Androgen receptor; Antagonist; Diazatricycloundecane; Prostate cancer

Indexed keywords

4 [3,5 DIOXO 11 OXA 4,9 DIAZATRICYCLO[5.3.1.0 2,6]UNDEC 4 YL] 2 TRIFLUOROMETHYL BENZONITRILE DERIVATIVE; ANTIANDROGEN; BENZONITRILE; BICALUTAMIDE; FLUTAMIDE; NILUTAMIDE; SEX HORMONE ANTAGONIST; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; DIELS ALDER REACTION; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; HUMANS; MALE; NITRILES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955425421     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.06.034     Document Type: Article

References (26)

1. A. Jemal, H. Thomas, T. Murray, and M. Thun CA Cancer J. Clin. 52 2002 23
2. K.L. Gao Drugs 43 1991 254
3. M. Motta, and M. Serio Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects 1998 Medicom Europe Amsterdam
4. E.D. Crawford, E.P. DeAntonio, F. Labrie, F.H. Schroder, and J. Geller J. Clin. Endocrinol. Metab. 80 1995 1062
5. G. Blackledge Cancer 1993 3830
6. A. Maucher, and E. von Angerer J. Cancer Res. Clin. Oncol. 119 1993 669
7. G. Sufrin, and D.S. Coffey Invest. Urol. 13 1976 429
8. A.S. Narayana, S.A. Loening, and D.A. Culp Br. J. Urol. 53 1981 152
9. C. Huggins, R. Stevens, and C.V. Hodges Arch. Surg. 43 1947 209
10. P. Westin, P. Stattin, J.-E. Damber, and A. Bergh Am. J. Pathol. 146 1995 1368
11. H. Scher, and C. Sawyers J. Clin. Oncol. 23 2005 8253
12. C.D. Chen, D.S. Welsbie, C. Tran, S.-H. Baek, R. Chen, R. Vessella, M.G. Rosenfeld, and C.L. Sawyers Nat. Med. 10 2004 33
13. E. Richter, S. Srivastava, and A. Dobi Prostate Cancer Prostatic Dis. 10 2007 114
14. C.J. Burd, L.M. Morey, and K.E. Knudsen Endocr. Relat. Cancer 13 2006 979
15. P.J.M. Hendriksen, N.F.J. Dits, K. Kokame, A. Veldhoven, W.M. van Weerden, C.H. Bangma, J. Trapman, and G. Jenster Cancer Res. 66 2006 5012
16. A. Balog, M. Salvati, W. Shan, A. Mathur, L. Leith, D. Wei, R. Attar, J. Geng, C. Rizzo, C. Wang, S. Krystek, J. Tokarski, J. Hunt, and R. Weinmann Bioorg. Med. Chem. Lett. 14 2004 6107
17. Salvati, M.; Balog, A.; Shan, W.; Wei, D.; Pickering, D.; Attar, R.; Geng, J.; Rizzo, C.; Gottardis, M.; Weinmann, R.; Krystek, S.; Sack, J.; An, Y.; Kish, K. Design, Structural Analysis and Biological Profile of a Novel Series of AR Antagonists, Poster Presentation, American Association of Cancer Research, 95th Annual Meeting, 2004
18. Salvati, M.; Balog, A.; Shan, W.; Geise, S. U.S. Patent 885,798, 2003.
19. M. Salvati, A. Balog, D. Wei, D. Pickering, R. Attar, J. Geng, C. Rizzo, J. Hunt, R. Weinmann, and R. Martinez Bioorg. Med. Chem. Lett. 15 2005 289
20. M. Salvati, A. Balog, W. Shan, R. Rampulla, S. Giese, T. Mitt, J.A. Furch, G.D. Vite, R.M. Attar, M. Jure-Kunkel, J. Geng, C.A. Rizzo, M.M. Gottardis, S.R. Krystek, J. Gougoutas, M.A. Galella, M. Obermeier, A. Aberra Fura, and G. Chandrasena Bioorg. Med. Chem. Lett. 18 2008 1910
21. Salvati, M. E.; Balog, A.; Pickering, D. A.; Giese, S.; Fura, A.; Li, W.; Patel, R.; Hanson, R. L.; Mitt, T.; Roberge, J.; Corte, J. R.; Spergel, S. H.; Rampulla, R. A.; Misra, R.; Xiao, H.-Y. World Patent Application WO 200306224.
22. Balog, A.; Fairfax, D.; Martin, G.; Salvati, M.; Xiao, H.-Y. U.S. 2007088029.
23. A.S. Narula, and S. Dev Tetrahedron Lett. 22 1969 1733
24. i) were determined in whole cells measuring displacement by tritiated DHT in the MDA-453 cell line. See Ref. 11 below for experimental details on assays.
25. Salvati, M.; Gottardis, M.; Krystek, Jr., S.; Attar, R.; Sack, J. U.S. 6,960,474; WO 2002000617.
26. For example, the in vitro metabolic stability of compound 37 was evaluated at 3 μM in the presence of human, rat, and mouse liver microsomes. After a 10 min incubation, the % compound remaining for compound 37 in humans, rats, and mice was 76%, 100%, and 92%, respectively.